FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

Who May Qualify: - Patient was diagnosed with MM, based on the IMWG criteria, and measurable disease at the time of diagnosis (appendix A). - Age ≥ 18 years. - Patient was treated with 12 cycles (13 cycles is accepted) of Dara-Rd and will continue treatment with Dara-Rd. Reduced dosing of lenalidomide, but not to less than 5 mg, and previous discontinuation or dose reduction of dexamethasone is allowed. - Partial response or better after treatment with 12 cycles of Dara-Rd, without signs of biochemical progression. - white blood cell count (ANC) at least 1.0x109/L and platelet count at least 75x109/L. - Patient is capable of giving willing to sign a consent form. - Written willing to sign a consent form. Who Should NOT Join This Trial: - Patient with non-secretory MM at diagnosis of the disease, i.e., before the start of treatment with Dara-Rd. - Patient in whom a plasmacytoma was the only measurable parameter at diagnosis of the disease, i.e., before the start of treatment with Dara-Rd. - Patient in whom urine M-protein was the only measurable parameter at diagnosis of the disease, i.e., before the start of treatment with Dara-Rd. - Patient in whom treatment with daratumumab, lenalidomide or both has been discontinued for whatever reason (patients may only have discontinued dexamethasone). - Patient in whom continuation of treatment with Dara-Rd is deemed not feasible because of medical reasons. - Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule. Always talk to your doctor about whether this trial is right for you.